Short Interest of The Day: DANDRIT BIOTECH USA INCORPORATED COMMON (OTCBB:DDRT) Shorted Shares Increased By 40%

December 1, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest of The Day: DANDRIT BIOTECH USA INCORPORATED COMMON (OTCBB:DDRT) Shorted Shares Increased By 40%

The stock of DANDRIT BIOTECH USA INCORPORATED COMMON (OTCBB:DDRT) registered an increase of 40% in short interest. DDRT’s total short interest was 700 shares in December as published by FINRA. Its up 40% from 500 shares, reported previously. With 5,600 shares average volume, it will take short sellers 0 days to cover their DDRT’s short positions. The stock closed at $1.55 during the last session. It is down 20.51% since May 4, 2016 and is downtrending. It has underperformed by 26.44% the S&P500.

DanDrit Biotech USA, Inc. is a biotechnology company. The company has a market cap of $15.27 million. The Firm focuses on developing vaccine against colorectal cancer. It currently has negative earnings. The Firm has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark).

DDRT Company Profile

DanDrit Biotech USA, Inc., incorporated on January 18, 2011, is a biotechnology company. The Firm focuses on developing vaccine against colorectal cancer. The Firm has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac (MCV) for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark).

More notable recent DanDrit Biotech USA Inc (OTCBB:DDRT) news were published by: Prnewswire.com which released: “DanDrit Biotech USA Inc. Announces The Purchase Of OncoSynergy, Inc.” on April 05, 2016, also Prnewswire.com with their article: “DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the …” published on April 28, 2015, Prnewswire.com published: “DanDrit Biotech and Riyadh Pharma Sign Partnership Agreement” on April 23, 2015. More interesting news about DanDrit Biotech USA Inc (OTCBB:DDRT) were released by: Reuters.com and their article: “DanDrit Biotech USA Inc announces final collaboration agreement with GISCAD Foundation” published on April 28, 2015 as well as Reuters.com‘s news article titled: “DanDrit Biotech USA Inc’s DanDrit Biotech and Riyadh Pharma sign partnership agreement” with publication date: April 23, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>